Retatrutide vs Pemvidutide
Side-by-Side Comparison
| Attribute | Retatrutide | Pemvidutide |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / Dual GLP-1/Glucagon Agonist |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon... | Pemvidutide is a dual-agonist peptide that activates both the GLP-1 receptor and the glucagon receptor. |
| Evidence Rating | B — Phase III / NDA Filed | C — Phase I–II Clinical Trials |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | Phase II completed (MOMENTUM for obesity, IMPACT for NASH/MASH). Phase III anticipated. |
| Safety Profile | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) | Common: nausea, vomiting, diarrhea, decreased appetite (consistent with GLP-1 agonist class); GI adverse events are dose-dependent and generally transient; similar profile to other GLP-1 agonists |
| Route | Subcutaneous (clinical trial formulation only) | Subcutaneous |
| Dose Range | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 | 1.2–2.4 mg SC once weekly (Phase 2 doses) |
| Frequency | Once weekly | Once weekly |
| Molecular Weight | N/A | N/A |
| Half-Life | ~6 days (allows once-weekly dosing) | Suitable for once-weekly dosing (exact value not publicly disclosed) |
Overview
Retatrutide and Pemvidutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. In the Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), the 12 mg dose achieved 24.2% mean body weight reduction at 48 weeks, with 100% of participants achieving at least 5% weight loss. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Pemvidutide — Mechanism & Evidence
Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist being developed by Altimmune for the treatment of obesity and nonalcoholic steatohepatitis (NASH/MASH). It is a once-weekly injectable peptide designed to combine GLP-1-mediated appetite suppression with glucagon-mediated increases in energy expenditure and hepatic fat reduction. Phase II trials (MOMENTUM and IMPACT) have been completed, showing promising weight loss and liver fat reduction. Phase III development is anticipated.
Key claims: Clinically meaningful weight loss in obesity; Substantial reduction in liver fat; Preserves lean body mass.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Retatrutide is also researched for: no additional unique applications.
Pemvidutide is also researched for: no additional unique applications.
Safety Considerations
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Pemvidutide: Common: nausea, vomiting, diarrhea, decreased appetite (consistent with GLP-1 agonist class) GI adverse events are dose-dependent and generally transient; similar profile to other GLP-1 agonists Heart rate increase observed, consistent with GLP-1 agonist class
Related Products
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Related Research News
Retatrutide Clinical Trial Results: Phase III TRIUMPH Data Shows Significant Weight Loss
Early reports from the Phase III TRIUMPH-1 trial suggest retatrutide, a novel triple agonist, has delivered substantial weight loss outcomes. These retatrutide clinical trial results indicate a potential shift in obesity treatment research, though full data analysis is pending.
Retatrutide Phase III TRIUMPH-1 Results: Unprecedented Weight Loss Reported at ADA26
Early reports from the American Diabetes Association 2026 meeting suggest retatrutide delivered unprecedented weight loss in the Phase III TRIUMPH-1 trial. Researchers and industry professionals are closely watching these retatrutide clinical trial results for implications in obesity and metabolic disease treatment.
Retatrutide Monthly Research Cost in Australia Breakdown
Researching Retatrutide (LY3437943), the most advanced triple GLP-1/GIP/glucagon receptor agonist, involves costs that vary by vial size, dose, and frequency. In Australia, a 10mg vial costs $129.99 AUD ($13.00/mg), while a 20mg vial is $199.99 AUD ($10.00/mg). Supplies like bacteriostatic water and needles add to monthly expenses, with planning around a 4-week reconstituted stability window essential to minimize waste.